Categories:
Update in Drug Regulation in China – Revocation of GMPc Requirements
On August 26, 2019, the Standing Committee of the National People’s Congress of China passed the A
Ler mais
Nitrosamine Medicinal Products Contamination – Scenario in Europe, United States, and Latin America – updated on July 19, 2023
In 2018, nitrosamine impurities, including N-nitrosodimethylamine (NDMA), were found in several bloo
Ler mais
ANVISA – Traceability/Serialization
After ten years of extensive debate, since the enactment of Law 11.903 / 2009, on November 13th, RDC
Ler mais
New Regulation for Stability Studies of Medicinal Products and APIs in Brazil – Resolution RDC 318/2019
On November 7, 2019, ANVISA published the Resolution RDC 318/2019, which defines the criteria for co
Ler mais
Importation procedures in Mexico – Mexican Foreign Trade Receipt System (Ventanilla Única de Comercio Exterior Mexicano – VUCEM)
The Mexican Foreign Trade Receipt System (VUCEM) is an integral service platform that facilitates ac
Ler mais
cGMP requirements for Latin American drug products MA submissions – updated 18th May 2021
A marketing authorization submission represents a major effort for the pharmaceutical industry, and
Ler mais
Latin America – Regulatory Agencies
Latin America is increasingly raising interest from pharmaceutical companies in other regions. It is
Ler mais
New Brazilian Regulatory Framework for API under Public Consultation
Approved by Anvisa’s Board of Directors, the Public Consultations of the New Regulatory Framew
Ler mais
EDQM- Published updated list of drafts of monographs for the European Pharmacopoeia
EDQM has published a statement with the updated list of substances which the drafts of its monograph
Ler mais